Bringing the fundamentals into focus…
Back to Akebia Therapeutics, Inc.
How Akebia Therapeutics, Inc. stacks up
AKBA · against 206 other Healthcare companies of similar size
Growth
48/ 100
Above the middle of the pack.
Ranked #93 of 207 · scores higher than 54% of peers
Bars: peers in each 10-point band of the growth score18 peers with a growth score of 40–49, including AKBA · Click a bar to see the companies
Why growth scores 48?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- slower revenue growth over three years: weaker than 62% of peers. 3-year revenue growth: 2.9% vs peer median 5.8%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
- Revenue growth is close to the peer norm. Revenue growth: 7.5% vs peer median 6.1%
Metric by metric
Position: dot = AKBA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | AKBA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 217 reported | 7.5% | 3.0% | 62% | 33% | |
| Earnings per share growthHigher is better · 84 reported | Not reported | 0.3% | — | — | 33% |
| 3-year revenue growthHigher is better · 200 reported | 2.9% | 3.5% | 48% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around AKBA| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 1 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 4 | 5.7B TWD (≈$177M) | 98 | 65 | |
| 4 | 217M AUD (≈$143M) | 98 | 43 | |
| 88 | 253M USD | 50 | 15 | |
| 91 | 406.2B KRW (≈$292M) | 49 | 51 | |
| 91 | 1.2B NOK (≈$115M) | 49 | 65 | |
| 93 | 2.7B CNY (≈$384M) | 48 | 65 | |
| 93 | 201M USD | 48 | 24 | |
| 93 | 19.8B INR (≈$238M) | 48 | 37 | |
| 96 | 460M SGD (≈$350M) | 47 | 46 | |
| 97 | 356M USD | 46 | 35 | |
| 97 | 200M USD | 46 | 30 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score